Introduction In recent years, the incidence of sepsis has increased in critically ill HIV/AIDS patients, and the presence of severe sepsis emerged as a major determinant of outcomes in this population. The inflammatory response and deregulated cytokine production play key roles in the pathophysiology of sepsis; however, these mechanisms have not been fully characterized in HIV/AIDS septic patients. Methods We conducted a prospective cohort study that included HIV/AIDS and non-HIV patients with septic shock. We measured clinical parameters and biomarkers (C-reactive protein and cytokine levels) on the first day of septic shock and compared these parameters between HIV/AIDS and non-HIV patients. Results We included 30 HIV/AIDS septic shock patients and 30 non-HIV septic shock patients. The HIV/AIDS patients presented low CD4 cell counts (72 [7-268] cells/mm3), and 17 (57%) patients were on HAART before hospital admission. Both groups were similar according to the acute severity scores and hospital mortality. The IL-6, IL-10 and G-CSF levels were associated with hospital mortality in the HIV/AIDS septic group; however, the CRP levels and the surrogates of innate immune activation (cytokines) were similar among HIV/AIDS and non-HIV septic patients. Age (odds ratio 1.05, CI 95% 1.02-1.09, p=0.002) and the IL-6 levels (odds ratio 1.00, CI 95% 1.00-1.01, p=0.05) were independent risk factors for hospital mortality. Conclusions IL-6, IL-10 and G-CSF are biomarkers that can be used to predict prognosis and outcomes in HIV/AIDS septic patients. Although HIV/AIDS patients are immunocompromised, an innate immune response can be activated in these patients, which is similar to that in the non-HIV septic population. In addition, age and the IL-6 levels are independent risk factors for hospital mortality irrespective of HIV/AIDS disease.
References
[1]
Dore GJ, Li Y, McDonald A, Ree H, Kaldor JM (2002) Impact of highly active antiretroviral therapy on individual AIDS-defining illness incidence and survival in Australia. J Acquir Immune Defic Syndr 29: 388-395. doi:10.1097/00126334-200204010-00010. PubMed: 11917244.
[2]
Palella FJ Jr, Baker RK, Moorman AC, Chmiel JS, Wood KC et al. (2006) Mortality in the highly active antiretroviral therapy era: Changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 43: 27-34. doi:10.1097/01.qai.0000233310.90484.16. PubMed: 16878047.
[3]
Pacheco AG, Tuboi SH, May SB, Moreira LF, Ramadas L et al. (2009) Temporal Changes in Causes of Death Among HIV-Infected Patients in the HAART Era in Rio de Janeiro, Brazil. J Acquir Immune Defic Syndr 51: 624-630. doi:10.1097/QAI.0b013e3181a4ecf5. PubMed: 19430304.
[4]
Rezende EL, Vasconcelos AM, Pereira MG (2010) Causes of death among people living with HIV/AIDS in Brazil. Braz J Infect Dis 14: 558-563. doi:10.1016/S1413-8670(10)70112-4. PubMed: 21340295.
[5]
Lucas S (2012) Causes of death in the HAART era. Curr Opin Infect Dis 25: 36-41. doi:10.1097/QCO.0b013e32834ef5c4. PubMed: 22156899.
[6]
Huang L, Quartin A, Jones D, Havlir DV (2006) Intensive Care of Patients with HIV Infection. N Engl J Med 355: 173-181. doi:10.1056/NEJMra050836. PubMed: 16837681.
[7]
Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J et al. (2001) Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 29: 1303-1310. doi:10.1097/00003246-200107000-00002. PubMed: 11445675.
[8]
Annane D, Aegerter P, Jars-Guincestre MC, Guidet B (2003) Current epidemiology of septic shock: The CUB-Réa Network. Am J Respir Crit Care Med 168: 165-172. doi:10.1164/rccm.2201087. PubMed: 12851245.
[9]
Andreu Ballester JC, Ballester F, González Sánchez A, Almela Quilis A, Colomer Rubio E (2008) Epidemiology of Sepsis in the Valencian Community (Spain), 1995–2004. Infect Control Hosp Epidemiol 29: 630–634. doi:10.1086/589583. PubMed: 18564905.
[10]
Beale R, Reinhart K, Brunkhorst FM, Dobb G, Levy M et al. (2009) Promoting Global Research Excellence in Severe Sepsis (PROGRESS): lessons from an international sepsis registry. Infection 37: 222-232. doi:10.1007/s15010-008-8203-z. PubMed: 19404580.
[11]
Blanco J, Muriel-Bombín A, Sagredo V, Taboada F, Gandía F et al. (2008) Incidence, organ dysfunction and mortality in severe sepsis: a Spanish multicentre study. Crit Care 12: R158. doi:10.1186/cc6914. PubMed: 19091069.
[12]
Martin GS, Mannino DM, Eaton S, Moss M (2003) The Epidemiology of Sepsis in the United States from 1979 through 2000. N Engl J Med 348: 1546-1554. doi:10.1056/NEJMoa022139. PubMed: 12700374.
[13]
Japiassú AM, Amancio RT, Mesquita EC, Medeiros DM, Bernal HB et al. (2010) Sepsis is a major determinant of outcome in critically ill HIV/AIDS patients. Crit Care 14: R152. doi:10.1186/cc8384. PubMed: 20698966.
[14]
Greenberg JA, Lennox JL, Martin GS (2012) Outcomes for critically ill patients with HIV and severe sepsis in the era of highly active antiretroviral therapy. J Crit Care 27: 51-57. doi:10.1016/j.jcrc.2011.08.015. PubMed: 22033058.
[15]
Riedemann NC, Guo RF, Ward PA (2003) The enigma of sepsis. J Clin Invest 112: 460-467. doi:10.1172/JCI200319523. PubMed: 12925683.
[16]
Bozza FA, Salluh JI, Japiassu AM, Soares M, Assis EF et al. (2007) Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis. Crit Care 11: R49. doi:10.1186/cc5836. PubMed: 17448250.
[17]
Ledwaba L, Tavel JA, Khabo P, Maja P, Qin J et al. (2012) Pre-ART levels of inflammation and coagulation markers are strong predictors of death in a South African cohort with advanced HIV disease. PLOS ONE 7(3): e24243. doi:10.1371/journal.pone.0024243. PubMed: 22448211.
[18]
Schleicher GK, Herbert V, Brink A, Martin S, Maraj R et al. (2005) Procalcitonin and C-reactive protein levels in HIV-positive subjects with tuberculosis and pneumonia. Eur Respir J 25: 688-692. doi:10.1183/09031936.05.00067604. PubMed: 15802344.
[19]
Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F et al. (2008) Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLOS Med 5: e203. doi:10.1371/journal.pmed.0050203. PubMed: 18942885.
[20]
Ross AC, Rizk N, O’Riordan MA, Dogra V, El-Bejjani D et al. (2009) Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis 49: 1119-1127. doi:10.1086/605578. PubMed: 19712036.
[21]
Le Gall , Lemeshow S, Saulnier F (1993) A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 270: 2957-2963. doi:10.1001/jama.1993.03510240069035. PubMed: 8254858.
[22]
Vincent JL, Moreno R, Takala J, Willatts S, de Mendon？a A et al. (1996) The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 22: 707-710. doi:10.1007/BF01709751. PubMed: 8844239.
[23]
Horan TC, Andrus M, Dudeck MA (2008) CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 36: 309-332. doi:10.1016/j.ajic.2008.03.002. PubMed: 18538699.
[24]
Thyrault M, Gachot B, Chastang C, Souweine B, Timsit JF et al. (1997) Septic shock in patients with the acquired immunodeficiency syndrome. Intensive Care Med 23: 1018-1023. doi:10.1007/s001340050451. PubMed: 9407236.
[25]
Coquet I, Pavie J, Palmer P, Barbier F, Legriel S et al. (2010) Survival trends in critically ill HIV-infected patients in the highly active antiretroviral therapy era. Crit Care 14: R107. doi:10.1186/cc8188. PubMed: 20534139.
[26]
Jacob ST, Moore CC, Banura P, Pinkerton R, Meya D et al. (2009) Severe sepsis in two Ugandan hospitals: a prospective observational study of management and outcomes in a predominantly HIV-1 infected population. PLOS ONE 4: e7782. doi:10.1371/journal.pone.0007782. PubMed: 19907656.
[27]
Rosenberg AL, Seneff MG, Atiyeh L, Wagner R, Bojanowski L et al. (2001) The importance of bacterial sepsis in intensive care unit patients with acquired immunodeficiency syndrome: implications for future care in the age of increasing antiretroviral resistance. Crit Care Med 29: 548-556. doi:10.1097/00003246-200103000-00013. PubMed: 11373418.
[28]
Haddy RI, Richmond BW, Trapse FM, Fannin KZ, Ramirez JA (2012) Septicemia in Patients With AIDS Admitted to a University Health System: A Case Series of Eighty-Three Patients. J Am Board Fam Med 25:318-322.
[29]
Benito N, Moreno A, Filella X, Miró JM, González J et al. (2004) Inflammatory responses in blood samples of human immunodeficiency virus-infected patients with pulmonary infections. Clin Diagn Lab Immunol 11(3): 608-614. PubMed: 15138189.
Gilstrap LG, Wang TJ (2012) Biomarkers and cardiovascular risk assessment for primary prevention: an update. Clin Chem 58(1): 72-82. doi:10.1373/clinchem.2011.165712. PubMed: 22125305.
[32]
Salluh JI, Lisboa T (2011) C-reactive protein in community-acquired sepsis: you can teach new tricks to an old dog. Crit Care 15: 186. doi:10.1186/cc10301. PubMed: 21955725.
[33]
Póvoa P, Salluh JI (2012) Biomarker-guided antibiotic therapy in adult critically ill patients: a critical review. Ann Intensive Care 23: 2 (1): 32. . PubMed : 22824162.
[34]
Póvoa P, Souza-Dantas VC, Soares M, Salluh JF (2011) C-reactive protein in critically ill cancer patients with sepsis: influence of neutropenia. Crit Care 15: R129. doi:10.1186/cc10242. PubMed: 21595932.
[35]
Gottlieb MS, Schroff R, Schanker HM, Weisman JD, Fan PT et al. (1981) Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med 305: 1425–1431. doi:10.1056/NEJM198112103052401. PubMed: 6272109.
[36]
Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G et al. (2006) Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 12: 1365–1371. PubMed: 17115046.
[37]
Cipolle MD, Pasquale MD, Cerra FB (1993) Secondary organ dysfunction. From clinical perspectives to molecular mediators. Crit Care Clin 9: 261-298. PubMed: 8490763.
[38]
Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF et al. (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344: 699-709. doi:10.1056/NEJM200103083441001. PubMed: 11236773.
[39]
Andaluz-Ojeda D, Bobillo F, Iglesias V, Almansa R, Rico L et al. (2012) A combined score of pro- and anti-inflammatory interleukins improves mortality prediction in severe sepsis. Cytokine 57: 332-336. doi:10.1016/j.cyto.2011.12.002. PubMed: 22197776.
[40]
Suratt BT, Eisner MD, Calfee CS, Allard JB, Whittaker LA et al. (2009) Plasma granulocyte colony-stimulating factor levels correlate with clinical outcomes in patients with acute lung injury. Crit Care Med 37: 1322-1328. doi:10.1097/CCM.0b013e31819c14fa. PubMed: 19242319.
Boumendil A, Angus DC, Guitonneau AL, Menn AM, Ginsburg C et al. (2012) Variability of intensive care admission decisions for the very elderly. PLOS ONE 7: e34387. doi:10.1371/journal.pone.0034387. PubMed: 22509296.
[43]
Deeks SG, Verdin E, McCune JM (2012) Immunosenescence and HIV. Curr Opin Immunol 24: 501-506. doi:10.1016/j.coi.2012.05.004. PubMed: 22658763.
[44]
Mera S, Tatulescu D, Cismaru C, Bondor C, Slavcovici A et al. (2011) Multiplex cytokine profiling in patients with sepsis. APMIS 119(2): 155-163. doi:10.1111/j.1600-0463.2010.02705.x. PubMed: 21208283.
[45]
Mrus JM, Braun L, Yi MS, Linde-Zwirble WT, Johnston JA (2005) Impact of HIV/AIDS on care and outcomes of severe sepsis. Crit Care 9: R623-R630. doi:10.1186/cc3811. PubMed: 16280060.
